ClinicalTrials.gg
RecruitingNCT02814942PEACHUpdated Mar 9, 2021

Prospective Evaluation of Asians With CRT for Heart Failure

An observational study in Heart Failure and Cardiac Resynchronisation Therapy, sponsored by National University Heart Centre, Singapore. Recruiting at 1 site in Singapore. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-09.

Sponsored by National University Heart Centre, Singapore · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 62 studies in Heart Failure with a site in Singapore — 6 open to participants now, 14 under way, 2 of them phase 3. Heart Failure · Singapore.

Planned enrollment
10th of 16
500 · median 678
Started
2011
with 1 other
Observational
16 of 62
1 open now
Primary completion
2030-12
later than 12 of 13 live
Registered
28th of 62
by date

Among the 62 studies in Heart Failure with a site in Singapore, this one is the 10th largest by planned enrollment of the 16 observational ones that give a count, is one of 2 that started in 2011, is one of 16 observational ones, reaches primary completion later than 12 of the 13 other live ones, and was the 28th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

6 of the 62 studies in Heart Failure with a site in Singapore are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Heart Failure with a site in Singapore, or all of them as a file.
02

Study summary

Aim:To determine the baseline characteristics of heart failure patients in Singapore undergoing cardiac resynchronization therapy (CRT); the long term outcome and predictors of response to CRT.

Methodology:Among patients undergoing CRT for severe heart failure according to indications stipulated in international Cardiology guidelines, baseline demographic data is collected. Age, gender, NYHA functional class, co-morbidities, QRS width on ECG, presence of left bundle branch block pattern on ECG, presence of atrial fibrillation, left ventricular ejection fraction (LVEF) on echocardiogram, ventricular dimensions, 6 min walk test distance are collected. In addition, during the CRT implant procedure, blood is drawn from the vascular access and analysed for NT-pro BNP levels and other biomarkers of heart failure.

The echocardiographic and ECG parameters and blood biomarkers are reanalysed at 6 months and 12 months following CRT implant. Response to CRT is defined as a reduction in the iLVESV (left ventricular end-systolic volume index to body surface area) of >/= 15% and/or an increase in the LVEF of >/= 10%.

Read the detailed description

Among patients undergoing CRT for severe heart failure according to indications stipulated in international Cardiology guidelines, baseline demographic data is collected. Age, gender, NYHA functional class, comorbidities, QRS width on ECG, presence of left bundle branch block pattern on ECG, presence of atrial fibrillation, left ventricular ejection fraction (LVEF) on echocardiogram, ventricular dimensions, 6 min walk test distance are collected. In addition, during the CRT implant procedure, blood is drawn from the vascular access and analysed for NT-pro BNP levels and other biomarkers of heart failure. The echocardiographic and ECG parameters and blood biomarkers are reanalysed at 6 months and 12 months following CRT implant. Response to CRT is defined as a reduction in the iLVESV (left ventricular end-systolic volume index to body surface area) of >/= 15% and/or an increase in the LVEF of >/= 10%.

03

Conditions studied

  • Heart Failure
  • Cardiac Resynchronisation Therapy

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Singaporean patients with broad QRS complexes, EF \<40%, heart failure, requiring CRT

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Broad QRS (>120 ms)
  • EF \< 40%
  • Symptomatic heart failure
  • Not on optimal medical therapy

Exclusion criteria

Exclusion Criteria:

  • Pregnant
  • \< 18 years of age
  • Infection
  • Unable to consent
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
8 Years
Patient registry
Yes
Biospecimen retention
Samples without dna

Groups and cohorts

  • Heart Failure receiving CRT

    Heart failure patients with QRS \> 120ms receiving CRT

    Device: Cardiac Resynchronization Therapy

Interventions

  • DeviceCardiac Resynchronization Therapy

    Cardiac resynchronization therapy with or without ICD

06

What researchers measure

Primary outcomes

  1. Echocardiographic response to CRT

    A subject is considered an echocardiographic responder to CRT if there is: 1. reduction in the iLVESV (left ventricular end-systolic volume index to body surface area) of \>/= 15% OR 2. an increase in the LVEF of \>/= 10% during follow-up echocardiography at 6 months

    Time frame: 6 months

Secondary outcomes

  1. Neuroendocrine response to CRT

    A subject is considered to have a neuro-endocrine response to CRT if BNP levels at 6 months post CRT implant has fallen more than 30% from baseline

    Time frame: 6 months

  2. Clinical response to CRT

    A subject is considered a positive clinical responder to CRT if: 1. NYHA class has improved by at least 1 class OR 2. 6 minutes walking test has increased by at least 10%

    Time frame: 6 months

  3. Hospitalization For Cardiovascular events

    Hospitalisation for acute coronary syndrome, heart failure, arrhythmias, ICD shocks or any unplanned admissions for any cardiac interventions or surgery

    Time frame: 8 years

  4. Mortality

    Mortality

    Time frame: 8 years

07

Study locations

1 of 1 sites recruiting
  • National University Hospital
    Singapore, Singapore
    Recruiting
    • Pipin Kojodjojo, MD PHD · Contact67795555
    • Swee Chong Seow, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011, a primary completion of Dec 2030 and a completion of Dec 2030. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2016
First posted
Jun 28, 2016
Start
Jan 2011
Primary completionEst.
Dec 2030
CompletionEst.
Dec 2030
Last update
Mar 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02814942
Lead sponsor
National University Heart Centre, Singapore
Responsible party
Pipin Kojodjojo (Consultant Cardiac Electrophysiologist, National University Heart Centre, Singapore) — Principal investigator
First posted
Jun 28, 2016
Start date
Jan 2011
Primary completion
Dec 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Mar 9, 2021

Study contacts

Pipin Kojodjojo, MD PHD
Contact
67795555
Swee Chong Seow, MD
principal investigator · National University Hospital, Singapore

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion